Myriad Genetics Inc (MYGN)
- Exchange
- NASDAQ
- Symbol
- MYGN
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Description
- Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
- Country
- USA
Stock price
At close: November 5, 2024
-
Open17.81
-
High17.96
-
Low17.35
-
Close17.61
-
Volume869,833
Financial ratios
Jun 30, 2024
Activity ratios
Liquidity ratios
Solvency ratios
Profitability ratios
Inventory turnover
25.98
Receivables turnover
6.75
Payables turnover
20.37
Working capital turnover
5.57
Days of inventory on hand (DOH)
14.05
Days of sales outstanding (DSO)
54.09
Number of days of payables
17.92
Fixed asset turnover
6.83
Total asset turnover
0.73
Current ratio
1.96
Quick ratio
1.44
Cash ratio
0.65
Cash conversion cycle
50.22
Debt-to-assets ratio
0.04
Debt-to-capital ratio
0.05
Debt-to-equity ratio
0.05
Financial leverage ratio
1.47
Interest coverage
-47.97
Gross profit margin
14.68%
Operating profit margin
-19.61%
Pretax margin
-19.70%
Net profit margin
-19.52%
Operating return on assets (Operating ROA)
-14.37%
Return on assets (ROA)
-14.30%
Return on total capital
-19.70%
Return on equity (ROE)
-20.96%